Clinical trial
GMZ2-Aluminum Hydroxide Phase I, Tübingen
NCT00397449 · European Vaccine Initiative, Other · Unknown status
Key facts
| NCT number | NCT00397449 |
|---|---|
| Title | GMZ2-Aluminum Hydroxide Phase I, Tübingen |
| Official title | Assessment of the Safety and Immunogenicity of the Recombinant Lactococcus Lactis Hybrid GMZ2 [GLURP+MSP3] a Malaria Vaccine in Healthy Adult Volunteers. A Phase I, Double-Blind, Randomised, Dose-Selection, Unicentre Trial |
| Lead sponsor | European Vaccine Initiative, Other |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Malaria |
| Intervention type | Biological |
| Interventions | GMZ2 (GLURP + MSP3 Hybrid) (malaria vaccine) |
| Enrollment | 30 |
| Start date | Oct 1, 2006 |
| Completion | Dec 1, 2007 |
| First posted | Nov 9, 2006 |
| Last update posted | Aug 10, 2007 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: